Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00754117 · ClinicalTrials.gov registry record
Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 8
- Enrollment target
NCT00754117 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 8 participants.
The verdict
NCT00754117 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1). Patients will then undergo 2 cycles of chemotherapy with R/CHOP. 14 to 21 days following cycle 2 of R/CHOP, patients will undergo repeat FDG-PET scan (PET-2). They will then complete therapy as planned. Following completion of therapy, standard response assessment will be performed, including CT scans of the chest, abdomen and pelvis and FDG-PET scan (PET-3).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-12-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00754117
The ClinicalTrials.gov registry entry for NCT00754117 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00754117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00754117 about?
NCT00754117 is a clinical study titled "Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)". Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1). Patients will then undergo 2 cycles of chemotherapy with R/CHOP. 14 to 21 days following cycle 2 of R/CHOP, patients will undergo repeat FDG-PET scan (PET-2). They will then complete therapy as planned. Follo...
What is the current status of trial NCT00754117?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2008-05. Estimated completion is 2012-12-08.
Who is sponsoring clinical trial NCT00754117?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.